A Rutgers observational study has identified three critical findings relevant to clinical practice and patient understanding. First, researchers documented an observational association between GLP-1 receptor agonist use and reduced violent behaviour in individuals with impulsive traits—however, this finding cannot establish cause-and-effect relationships and requires further validation through randomised trials.
Second, the neurobiological rationale is compelling: GLP-1 receptors are highly active in the prefrontal cortex (impulse control, 95%), amygdala (emotional regulation, 76%), and reward centres, suggesting plausible mechanisms for behavioural effects. Third, and most importantly, these medications remain approved solely for diabetes and weight management. Off-label use for impulse control or violence reduction is not supported by current evidence and would be inappropriate outside research settings. Clinicians should await rigorously designed trials before considering any expanded therapeutic applications.
Read the full article on GMJ Newsroom.
Was this article helpful?
